AIM ImmunoTech Inc. (AIM)
ASE · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 25K | 26K | 21K | 22K |
| Gross Profit | 15K | -42K | -19K | 18K |
| Operating Income | -2.6M | -2.4M | -3.0M | -2.2M |
| Net Income | -2.8M | -3.3M | -4.2M | -3.0M |
| Diluted EPS | $-3.68 | $-1.57 | $nan | $-0.69 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 141K | 202K | 170K | 88K |
| Gross Profit | 141K | 160K | 139K | -40K |
| Operating Income | -19.9M | -31.9M | -19.8M | -11.7M |
| Net Income | -19.4M | -29.0M | -17.3M | -14.0M |
| Diluted EPS | $-39.96 | $-59.94 | $-30.92 | $-8.62 |